checkAd

     148  0 Kommentare The Capital Group holds 10.03% of Galapagos shares

    Mechelen, Belgium; 9 February 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

    Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 5 February 2021 from The Capital Group Companies, Inc., that it holds 10.03% of the current 65,411,767 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed above the 10% threshold of Galapagos’ voting rights by purchase of voting securities on 22 January 2021. The full transparency notice is available on the Galapagos website.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Galapagos!
    Long
    24,71€
    Basispreis
    0,20
    Ask
    × 13,30
    Hebel
    Short
    27,83€
    Basispreis
    0,20
    Ask
    × 13,25
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    About Capital Group
    Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (“CGII”), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 6,563,320 of Galapagos’ voting rights, consisting of ordinary shares (6,559,874) and equivalent financial instruments (right to recall lent American Depository Shares) (3,446), which represents 10.03%.

    About Galapagos
    Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

    Contacts

    Investors:
    Elizabeth Goodwin
    VP Investor Relations
    +1 781 460 1784

    Sofie Van Gijsel
    Senior Director Investor Relations
    +32 485 19 14 15
    ir@glpg.com

    Media:
    Carmen Vroonen
    Global Head Communications & Public Affairs
    +32 473 824 874

    Lesen Sie auch

    Anna Gibbins
    Senior Director Therapeutic Areas Communications
    +44 7717 801900
    communications@glpg.com



    1  Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market



     

     

    Attachment




    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    The Capital Group holds 10.03% of Galapagos shares Mechelen, Belgium; 9 February 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant to Belgian transparency legislation1, …